Publications

PUBLICATIONS FOR PROJECT 1:

  • Chen G, Prchal JT. Polycythemia vera and its molecular basis: An update. Best Pract Res Clin Haematol. 2006;19(3):387-97.
  • Bellanne-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C, Delhommeau F, Casadevall N, Vainchenker W, Thomas G, Najman A. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006 Jul 1;108(1):346-52.
  • Prchal, JT Does JAK2 1849G>T initiate polycythemia vera? Blood, Jul 2006; Inside Blood. 108: 8 - 9.
  • Popat U, Frost A, Liu E, Guan Y, Durette A, Vishnu R, Prchal JT. High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK 2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. Blood. 2006 107: 3486 – 3488.
  • Vahid Afshar-Kharghan and Josef Prchal. Does Janus Have Three Faces? The Hematologist, 3(6):5, 2006.
  • Prchal, JT. Erythropoietin-independent erythroid colonies: Is the molecular basis clarified? Blood, Sep 2006; Inside Blood. 108: 1431 - 1432.
  • Henshaw M, Prchal, JT.. Minireview: Uniparental Disomy in Polycythemia Vera and in Other Malignancies. The Hematologist, 4(1):5, 2007.
  • Chen GL, Liu E, Naidoo K, Popat U, Coetzer TL, Prchal JT. Idiopathic myelofibrosis without dacryocytes. Haematologica. 2006 Jun;91:ECR29
  • Xiong Z, Liu E, Yan Y, Silver RT, Yang F, Chen IH, Chen Y, Verstovsek S, Wang H, Prchal J, Yang XF. An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions. J Immunol. 2006 Oct 1;177(7):4907-16
  • Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, Ingram DA. Re-defining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2006 Oct 19
  • Nussenzveig RH, Lingam HB, Gaikwad A, Zhu Q, Jing N, Prchal JT. A novel mutation of the cytochrome-b5 reductase gene in an Indian patient: the molecular basis of type I methemoglobinemia. Haematologica. 2006 Nov;91(11):1542-5.
  • Xiong Z, Yan Y, Liu E, Silver RT, Verstovsek S, Yang F, Wang H, Prchal J, Yang X-F. Novel Tumor Antigens Elicit Anti-Tumor Humoral Immune Reactions In A Subset Of Patients With Polycythemia Vera. Clinical Immunology. 2006 Nov 16; [Epub ahead of print]
  • Nussenzveig RH, Swierczek SI, JJelinek J, Gaikwad A, Liu E, Verstovsek S, Prchal JF and Prchal JT. Polycythemia Vera is not Initiated by JAK2(V617F) Mutation. Experimental Hematology. 35: 32-38, 2007.
  • Hoffman R, Prchal JT, Samuelson S, Ciurea SO, Rondelli D. Philadelphia Chromosome-Negative Myeloproliferative Disorders: Biology and Treatment. Biol Blood Marrow Transplant. 2007 Jan;13S1:64-72.
  • Gaikwad A, Nussenzveig R, Liu E, Gottshalk S, Chang K, Prchal JT. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2(V617F) allele. Exp Hematol. 2007 Apr;35(4):587-95.
  • Gaikwad A, Verstovsek S, Nussenzveig R, Yoon, D, Chang KT, Nussenzveig R, Cortez J, Wainchenker W, Prchal JT. Imatinib Effect on Growth and Signal Transduction in Polycythemia Vera. Exp Hematol. 2007 in press
  • Bruchova/Votavova H, Yoon D, Prchal JT. MiR-451 Enhances Erythroid Differentiation in K562 cells. Leukemia and Lymphoma, Leuk Lymphoma. 2010 Apr;51(4):686-93.], PMID: 20218812.
  • Chen AT, Prchal JT. JAK2 kinase inhibitors and myeloproliferative disorders. Curr Opin Hematol. 2010 Mar;17(2):110-6., PMID: 20087176
  • Teman CJ, Wilson AR, Perkins SL, Hickman K, Prchal JT, Salama ME. Quantification of fibrosis and osteosclerosis in myeloproliferative neoplasms: A computer-assisted image study. Leuk Res. 2010 Jul;34(7):871-6., PMID: 20122729
  • Simonson TS, Yang Y, Huff CD, Yun H, Qin G, Witherspoon DJ, Bai Z, Lorenzo FR, Xing J, Jorde LB, Prchal JT, Ge R. Genetic Evidence for High-Altitude Adaptation in Tibet. Science. 2010 Jul 2;329(5987):72-5, PMID: 20466884
  • Perrotta S, Cucciolla V, Ferraro M, Ronzoni L, Tramontano A, Rossi F, Scudieri AC, Borriello A, Roberti D, Nobili B, Cappellini MD, Oliva A, Amendola G, Migliaccio AR, Mancuso P, Martin-Padura I, Bertolini F, Yoon D, Prchal JT, Della Ragione F. EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors. PLoS One. 2010 Aug 5;5(8). pii: e12015. PMID: 20700488.
  • Riaz Ahmed KB, Warner SL, Chen A, Gourley ES, Liu X, Vankayalapati H, Nussenzveig R, Prchal JT, Bearss DJ, Parker CJ. In Vitro and In Vivo Characterization of SGI-1252, a Small Molecule Inhibitor of JAK2. Exp Hematol. 2011 Jan;39(1):14-25, PMID: 20934482.
  • Samuelson S, Sandmaier BM, Heslop HE, Popat U, Carrum G, Champlin RE, Storb R, Prchal JT, Gooley TA, Joachim Deeg H. Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. Br J Haematol. 2011 Apr;153(1):76-82. doi: 10.1111/j.1365-2141.2011.08582. PMID: 21323890.
  • Swierczek SI, Yoon D, Bellanne'-Chantelot C, Kim S, Saint-Martin C, Delhommeau F, Najman A, Prchal J. Extent of hematopoietic involvement by TET2 mutations in JAK2V617F polycythemia vera. Haematologica. 2011 May;96(5):775-8. PMID: 21273266.
  • Yoon D, Ponka P, Prchal JT. Hypoxia and Hematopoiesis. Am J Physiol Cell Physiol. 2011 300:C1215-C1222, 2011 PMID: 21368293.
  • Miasnikova G, Sergueeva AI, Nouraie M, Niu X, Okhotin DJ, Polyakova LA, Ganz T, Prchal JT, Gordeuk V. The heterozygote advantage of the Chuvash polycythemia VHLR200W mutation may be protection against anemia. Haematologica. 2011 Sep;96(9):1371-4. PMID: 21606165.
  • Bluteau D, Gilles L, Hilpert M, Antony-Debré I, James C, Debili N, Camara-Clayette V, Wagner-Ballon O, Cordette-Lagarde V, Robert T, Ripoche H, Gonin P, Swierczek S, Prchal J, Vainchenker W, Favier R, Raslova H. Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia (FPD/AML). Blood. 2011 Dec 8;118(24):6310-20. PMID: 21725049.
  • Wang K, Swierczek S, Hickman K, Hakonarson H, Prchal JT. Convergent mechanisms of somatic mutations in polycythemia vera. Discovery Medicine 2011 Jul;12(62):25-32. PMID: 21794206.
  • Prchal JT. Interferon and PV stem cells. Blood. 2011 Aug 11;118(6):1429-30. PMID: 21835958
  • Gordeuk VR, Miasnikova GY, Sergueeva AI, Niu X, Nouraie M, Okhotin DJ, Polyakova LA, Ammosova T, Nekhai S, Ganz T, Prchal JT. Chuvash polycythemia VHLR200W mutation is associated with downregulation of hepcidin expression. Blood. 2011 Nov 10;118(19):5278-82. PMID: 21876117.
  • Swierczek SI, Piterkova L, Jelinek J, Agarwal N, Hammoud S, Wilson A, Hickman K, Parker CJ, Cairns B, Prchal JT. Methylation of AR locus does not always reflect X chromosome inactivation state. Blood. 2012 Mar 29;119(13):e100-9], PMID: 22286197.
  • Nussenzveig RH, Burjanivova T, Salama ME, Ogilvie NW, Marcinek J, Plank L, Agarwal AM, Perkins SL, Prchal JT. Detection of JAK2 Mutations in Paraffin Marrow Biopsies by High Resolution Melting Analysis: Identification of L611S alone and in cis with V617F in Polycythemia Vera. Leuk Lymphoma. 2012 Jul 9. PMID: 22642932.
  • Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T, Kebebew E, Popovic V, Stratakis CA, Prchal JT*, Pacak K*. (*senior authors). Somatic HIF2 Gain-of-Function Mutations in Paraganglioma with Polycythemia. N Engl J Med., 2012 Sep 6;367(10):922-930; PMID: 22931260.
  • Rogers H, Wang L, Yu X, Alnaeeli M, Cui K, Zhao K, Bieker JJ, Prchal J, Huang S, Weksler B, Noguchi CT. T-cell Acute Leukemia 1 (TAL1) regulation of erythropoietin receptor and association with excessive erythrocytosis. J Biol Chem. 2012 Oct 26;287(44):36720-31PMID: 22982397.
  • McClain DA, Abuelgasim KA, Nouraie M, Salomon-Andonie J, Niu X, Miasnikova G, Polyakova LA, Sergueeva A, Okhotin DJ, Cherqaoui R, Okhotin D, Cox JE, Swierczek S, Song J, Simon MC, Huang J, Simcox JA, Yoon D, Prchal JT, Gordeuk VR. Decreased serum glucose and glycosylated hemoglobin levels in patients with Chuvash polycythemia: a role for HIF in glucose metabolism. J Mol Med (Berl). 2013 Jan;91(1):59-67. doi: 10.1007/s00109-012-0961-5. PMID: 23015148.
  • Lorenzo FR, Yang C, Ng Tang Fui M, Vankayalapati H, Zhuang Z, Huynh T, Grossmann M, Pacak K, Prchal JT. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl). J Mol Med (Berl). 2013 Apr;91(4):507-12.PMID: 23090011.
  • Prchal JT. Molecular basis of polycythemic disorders due to aberrant hypoxia sensing and its relevance to acute leukemia. Best Pract Res Clin Haematol. 2012 Dec;25(4):493-7. doi: 10.1016/j.beha.2012.10.014.. PMID: 23200548.
  • Swierczek S, Nausova J, Jelinek J, Liu E, Roda P, Kucerova J, Jarosova M, Urbankova H, Indrak K, Prchal JT, Divoky V. Concomitant JAK2 V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells. Am J Hematol. 2013 Feb;88(2):157-8. 10.1002/ajh.23362. PMID: 23280542.
  • Yang C, Sun MG, Matro J, Huynh TT, Rahimpour S, Prchal JT, Lechan R, Lonser R, Pacak K, Zhuang Z. Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. Blood. 2013 Mar 28;121(13):2563-6. doi: 10.1182/blood-2012-10-460972. PMID: 23361906.
  • Szankasi P, Reading NS, Vaughn CP, Prchal JT, Bahler DW, Kelley TW A Quantitative Allele-Specific PCR Test for the BRAF V600E Mutation Using a Single Heterozygous Control Plasmid for Quantitation: A Model for qPCR Testing without Standard Curves. J Mol Diagn. 2013 Mar;15(2):248-54. PMID: 23313362.
  • Zangari M, Fink L, Tolomelli G, Lee JC, Stein BL, Hickman K, Swierczek S, Kelley TW, Berno T, Moliterno AR, Spivak JL, Gordeuk VR, Prchal JT. Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera? Blood Coagul Fibrinolysis. 2013 Apr;24(3):311-316; PMID: 23392352.
  • Ljubas Tomasic NL, Piterkova L, Huff C, Bilic E, Yoon D, Miasnikova G, Sergueeva AI, Niu X, Nekhai S, Gordeuk V, Prchal J. Polycythemia due to Croatian homozygous VHL (571C>G:H191D) mutation has a different phenotype than Chuvash polycythemia (VHL 598C>T:R200W). Haematologica. 2013 April 2013 98: 560-567; PMID: 23403324.
  • Pacak K, Jochmanova I, Prodanov T, Yang C, Merino MJ, Fojo T, Prchal JT, Tischler AS, Lechan RM, Zhuang Z. New Syndrome of Paraganglioma and Somatostatinoma Associated With Polycythemia. J Clin Oncol. 2013 May 1;31(13):1690-8. doi: 10.1200/JCO.2012.47.1912 PMID: 23509317.
  • Lanikova L, Lorenzo F, Yang C, Vankayalapati H, Drachtman R, Divoky V, Prchal JT. Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer. Blood. 2013 May 9;121(19):3918-24. doi: 10.1182/blood-2012-11-469296.
  • Prchal JT, Gordeuk VR. Treatment target in polycythemia vera. N Engl J Med. 2013 Apr 18;368(16):1555-6. doi: 10.1056/NEJMc1301262#SA3. PMID: 23594015.
  • Lorenzo FR, Yang C, Lanikova L, Butros L, Zhuang Z, Prchal JT. Novel compound VHL heterozygosity (VHL T124A/L188V) associated with congenital polycythaemia. Br J Haematol. 2013 Sep;162(6):851-3 doi: 10.1111/bjh.12431. PMID: 23772956.
  • Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Leibundgut EO, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, Nickless G, Guglielmelli P, van der Reijden BA, Jansen JH, Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill K, McLornan D, Yeoman K, Akiki S, Bryon J, Jeffries S, Jones A, Percy MJ, Schwemmers S, Gruender A, Kelley TW, Reading S, Pancrazzi A, McMullin MF, Pahl HL, Cross NC, Harrison CN, Prchal JT, Chomienne C, Kiladjian JJ, Barbui T, Grimwade D. Establishing optimal Quantitative-Polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F associated myeloproliferative neoplasms: a joint European Leukemianet/ MPN&MPNr-EuroNet (COST Action BM0902) study. Leukemia. 2013 Jul 17. doi: 10.1038/leu.2013.219. [Epub ahead of print] PMID: 23860450.
  • Ye Z, Liu CF, Lanikova L, Dowey SN, He C, Huang X, Brodsky RA, Spivak JL, Prchal JT, Cheng L. Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient iPSCs. Stem Cells. 2013 Sep 18. doi: 10.1002/stem.1545. [Epub ahead of print]. PMID: 24105986.

PUBLICATIONS FOR PROJECT 2:

  • Schwemmers S, Will B, Waller CF, Abdulkarim K, Johansson P, Andreasson B, Pahl HL (2007) JAK2V617F-negative ET Patients do not display constitutively active JAK/STAT signaling. Exp. Hematol, 35: 1695 – 1703.
  • Cario H, Schwarz K, Herter JM, Komrska V, McMullin MF, Minkov M, Niemeyer C, Pospisilova D, Reinhard H, Debatin KM, Pahl HL (2008) Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera. Br. J. Haematol., 142: 622 - 626.
  • Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, Cario H, Pahl HL, Reiter A, Grand F, Cross NCP (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms, Nature Genetics, 41: 446 – 449.
  • Cario H, McMullin MF, Pahl HL (2009) Clinical and hematological presentation of children and adolescents with polycythemia vera, Ann. Hematol., 88: 713 - 719.
  • Mutschler M, Magin AS, Buerge M, Roelz R, Schanne DH, Will B, Pilz I, Migliaccio AR, Pahl HL (2009) NF-E2 Overexpression Delays Erythroid Maturation and Increases Erythrocyte Production, British J. Haematol., 146: 203 - 217.
  • Wang W, Schwemmers S, Hexner EO, Pahl HL (2010) AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2. Blood, 116: 254 – 268.
  • Roelz R, Pilz IH, Mutschler M, Pahl HL (2010) Of Mice and Men: Human RNA Polymerase III Promoter U6 is more efficient than its murine homologue for shRNA Expression from a Lentiviral Vector in both Human and Murine Progenitor Cells. Exp. Hematol., 38: 792 – 797.
  • Kaufmann KB, Gründer A, Hadlich T, Wehrle J, Gothwal M, Bogeska R, Seeger TS, Kayer S, Pham KB, Jutzi JS, Ganzenmüller L, Steinemann D, Schlegelberger B, Wagner JM, Jung M, Will B, Steidl U, Aumann K, Werner M, Günther T, Schüle R, Rambaldi A, Pahl HL, (2012) A novel murine model of myeloproliferative disorders generated by overexpressionof the transcription factor NF-E2. J. Exp. Med, 209: 35 - 50.
  • Pahl HL (2012) A JAK in the cell cycle. Blood, 119:1096-1097.
  • Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA. (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs., J. Clin. Oncol. 30: 4098-4103.
  • Bogeska R, Pahl HL (2013) Elevated NF-E2 levels promote Epo-independent erythroid maturation and recapitulate the HSC and CMP expansion observed in polycythemia vera patients. Stem Cells Translational Medicine, 2: 112 - 117.
  • Wehrle J, Seeger TS, Schwemmers S, Pfeifer D, Bulashevska A , Pahl HL (2013) Transcription factor NF-E2 mediates expression of the cytoine IL8, a known predictor of inferior outcome in MPN patients. Haematologica, 98: 1073 -1080.
  • Jutzi JS, Bogeska R, Nikoloski G, Schmid CA, Seeger TS, Stegelmann F, Schwemmers S, Gründer A, Peeken J, Gothwal M, Wehrle J, Aumann K, Hamdi K, Dierks, C, Wang W, Döhner K, Jansen JH, Pahl HL (2013) MPN patients harbor recurrent truncating mutations in transcription factor NF-E2, J. Ex. Med, 210: 1003 - 1019.
  • Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, Nickless G, Guglielmelli P, van der Reijden BA, Jansen JH, Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill K, McLornan D, Yeoman K, Akiki S, Bryon J, Jeffries S, Jones A, Percy MJ, Schwemmers S, Gruender A, Kelley TW, Reading S, Pancrazzi A, McMullin MF, Pahl HL, Cross NCP, Harrison CN, Prchal JT, Chomienne C, Kiladjian JJ, Barbui T, Grimwade D (2013) Establishing Optimal Quantitative-Polymerase Chain Reaction Assays for Routine Diagnosis and Tracking of Minimal Residual Disease in JAK2-V617F associated Myeloproliferative Neoplasms: A Joint European LeukemiaNet/ MPN&MPNr-EuroNet (COST Action BM0902) Study. Leukemia, 27: 2032 – 2039.
  • Aumann K, Frey AV, May AM, Hauschke D, Kreutz C, Marx JP, Timmer J, Werner M, Pahl HL (2013) Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates pre-fibrotic primary myelofibrosis from essential thrombocythemia. Blood, 122: 93 - 99.

PUBLICATIONS FOR PROJECT 3:

  • Pemmaraju, N, Moliterno, AR, Williams, DM, et al. The Quantitative JAK2 V617F Neutrophil Allele Burden does Not Correlate with Thrombotic Risk in Essential Thrombocytosis. Leukemia 21:2210, 2007.
  • Williams, D M Kim, A H, Rogers, O., et al. Genotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis and idiopathic myelofibrosis. Exp Hematol. 35:1641, 2007
  • Moliterno, AR, Williams, DM, Rogers, R et al. Phenotypic variability within the JAK2 V617F-positive MPD: the roles of progenitor cell and neutrophil allele burdens. Exp Hematol.36:1460, 2008
  • Ye Z, Zhan H, Mali P et al. Human induced pluripotent stems from blood cells of healthy donors and patients with acquired blood disorders. Blood 114:5473, 2009.
  • Stein B, Williams DM, Wang N-Y, Rogers O, Isaacs MA, Pemmaraju N, Spivak JL and Moliterno AR. Sex differences in the JAK2 V617F allele burden in the chronic myeloproliferative disorders. Haematologica, 95:1090, 2010.
  • Stein B, Williams DM, Rogers O, et al. Disease burden at the stem cell level is a feature of primary myelofibrosis; a multivariable analysis of 164 JAK2 V617F –positive myeloproliferative neoplasm patients. Exp. Hematol 39: 95, 2011.
  • Stein BL, Rademaker A W Spivak, JL and Moliterno, AR. Gender and vascular complications in the JAK2 V617F-positive Myeloproliferative Neoplasms. 2011, Thrombosis, Epub, 2011.
  • Stein BL, Williams, DA, O’Keefe C, et. al. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemic myelofibrosis but not in essential thrombocytosis and polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica 96: 1462, 2011
  • Ye Z, Liu CF, Lanikova L, et.al. Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient iPSCs. Stem Cells. 2013 in press.

PUBLICATIONS FOR PROJECT 4:

  • Zetterberg E, Vannucchi AM, Migliaccio AR, Vanchenker W, Tulliez M, Rogers R, Palmblad J. Pericyte coverage of abnormal blood vessels in myelofibrosis bone marrows. Haematologica, in press.
  • Ghinassi B, Sanchez M, Martelli F, Amabile G, Vannucchi AM, Migliaccio M, Orkin SH, Migliaccio AR, The hypomorphic Gata1low mutation alters the proliferation/ differentiation potential of the common megakaryocytic-erythroid progenitor, Blood, 2007, 109:1460-1473.
  • Guglielmelli P, Zini R, Bogani C, Salati S, Pancrazi A, Bianchi E, Mannelli F, Ferrari S, Le Bousse-Kerdiles MC, Bosi A, Barosi G, Migliaccio AR, Manfredini R, Vannucchi AM. Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms Tumor 1. Stem Cells, 2007, 25:165-173.
  • A Di Baldassarre, C Di Rico, A Di Noia, T Bonfini, A Iacone, M Marchisio, S Miscia, E Alfani, AR Migliaccio, G. Stamatoyannopoulos and G Migliaccio: Protein Kinase C (PKC)alpha is differentially activated during neonatal and adult erythropoiesis and favors expression of a reporter gene under the control of the Aγ-promoter in cellular models of hemoglobin switch. J Cell Biochem 2007, published ahead of print on Jan 9.
  • Ghinassi B, M. Verrucci, Di Noia A, Migliaccio G, Migliaccio AR. Transcriptional and prost-transcriptional growth factor control of the expression of lineage-specific transcription factors during erythroid differentiation, Exp Hematol, in press.
  • Sanchez M, Weissman IL, Pallavicini M, Valeri M, Vannucchi AM, Migliaccio G, Migliaccio AR: Differential amplification of murine bipotent megakaryocytic/erythroid “progenitor” and “precursor” cells during the recovery from acute and chronic erythroid stress. Stem Cells. 2006; 24:337-348.
  • Migliaccio, AR, Vannucchi AM, Migliaccio G., Hoffman R. Molecular advances toward the understanding of the patho-biology of idiopathic myelofibrosis. Curr Imm Rev, 2006, 2: 169-186.
  • Vannucchi AM, Villeval J-L, Wagner-Ballon O, Guglielmelli P, Migliaccio AR, Animals Models of Myelofibrosis, Source Book of Models for Biomedical Research. MP Conn, editor, The Humana Press Inc, in press
  • Migliaccio AR, Rana RA. Role of Thrombopoietin in mast cell differentiation. Ann N Y Acad Sci, 2007, in press.
  • Hricik T, Federici G, Zeuner A, Alimena G, Tafuri A, Tirelli V, Varricchio L, Masiello F, Ciaffoni F, Vaglio S, Petricoin EF, Girelli G, Levine RL, Migliaccio AR. Am J Hematol. 2013 Sep;88(9):723-9. doi: 10.1002/ajh.23487. Epub 2013 Jul 3. Transcriptomic and phospho-proteomic analyzes of erythroblasts expanded in vitro from normal donors and from patients with polycythemia vera. PMID: 23720412 [PubMed - in process]
  • Zingariello M, Martelli F, Ciaffoni F, Masiello F, Ghinassi B, D'Amore E, Massa M, Barosi G, Sancillo L, Li X, Goldberg JD, Rana RA, Migliaccio AR. Blood. 2013 Apr 25;121(17):3345-63. doi: 10.1182/blood-2012-06-439661. Epub 2013 Mar 5. Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis. PMID: 23462118 [PubMed - indexed for MEDLINE]
  • Poletto V, Rosti V, Villani L, Catarsi P, Carolei A, Campanelli R, Massa M, Martinetti M, Viarengo G, Malovini A, Migliaccio AR, Barosi G. A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation. Blood. 2012 Oct 11;120(15):3112-7. doi: 10.1182/blood-2012-05-433466. Epub 2012 Aug 9. PMID: 22879541[PubMed - indexed for MEDLINE]

PUBLICATIONS FOR PROJECT 5:

  • Rosti V, Massa M, Vannucchi AM, Bergamaschi G, Campanelli R, Pecci A, Viarengo G, Meli V, Marchetti M, Guglielmelli P, Bruno E, Xu M, Hoffman R, Barosi G; on behalf of the Investigators of the Italian Registry of Myelofibrosis with Myeloid Metaplasia and the Myeloproliferative Disorders Research Consortium. The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis. 2007 May-Jun;38(3):280-6. Epub 2007 Mar 9.
  • Wen-Yang Hu, Yan Zhao, Wei Zhang, Takefumi Ishii, Jun Shi, Selcuk Sozer, Edward Bruno, Valerie Lindgren, Mingjiang Xu, Ronald Hoffman. Phenotypic characterization of tumor stem cells from idiopathic myelofibrosis by IL3-Rα. Experimental Hematology, submitted.
  • Ciurea S, Merchant D, Mahmud N, Bruno E, Ishii T, Xu M, Hofman R. In vitro megakaryocytopoiesis in idiopathic myelofibrosis. Blood (in revision)
  • Shi J, Zhao Y, Ishii T, Sozer S, Bruno E, Lindgren V, Xu M, Hoffman R. Effects of chromatin modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Research (in press).
  • Hu W, Zhao Y, Ishii T, Sozer S, Shi J, Zhang W, Bruno E, Hoffman R, Xu M. Hematopoietic cell lineage distribution of MPLW515L/K mutations in patients with idiopathic myelofibrosis. Br. J. Hematol 2007 Apr 4; [Epub ahead of print].
  • Hoffman R, Prchal JT, Samuelson S, Ciurea SO, Rondelli D. Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. Biol Blood Marrow Transplant. 2007 Jan;13(1 Suppl 1):64-72.
  • Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Chen HY, Mahmud N, Quigley J, Hoffman R, Jessop E, Beri R, Rondelli D. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006 Oct;38(7):477-82.
  • Ishii T, Xu M, Zhao Y, Hu W-Y, Ciurea S, Bruno E, Hofman R. Recurrence of clonal hematopoiesis after discontinuing pegylated recombinant interferon-α 2a in a patient with polycythemia vera. Leukemia. 2007 Feb;21(2):373-4.
  • Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 108, 3128-3134 (2006).
  • Hoffman R and Xu M. Is Bone Marrow Fibrosis the Real Problem? Blood 107, 3421-3422 (2006)

PUBLICATIONS FOR PROJECT 6:

  • Barosi G, Gattoni E, Guglielmelli P, Campanelli R, Facchetti F, Fisogni S, Goldberg J, Marchioli R, Hoffman R, Vannucchi AM. Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. Am J Hematol. 2010 Aug;85(8):616-9.
  • Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011 May 5;117(18):4706-15.
  • Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood. 2012 Aug 16;120(7):1367-79.
  • R. A. Mesa, R. T. Silver, S. Verstovsek, J. Mascarenhas,, C. M. Kessler, D. Rondelli, J.D. Goldberg, R. Marchioli, E. P. Demakos, L. R. Silverman, , R. Hoffman. Single Agent Bevacizumab for Myelofibrosis: Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Trial. 2013. Haematologica. 2013 Sep;98(9):1421-3.

OTHER PUBLICATIONS:

  • Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP, Spivak JL, Smith BD, Klingemann HG, Fruchtman S, Hoffman R; Myeloproliferative Diseases-Research Consortium. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood. 2005 May 15;105(10):4115-9. Epub 2005 Jan 25. PMID: 15671439
  • Ni H, Barosi G, Rondelli D, Hoffman R. Studies of the site and distribution of CD34+ cells in idiopathic myelofibrosis.Am J Clin Pathol. 2005 Jun;123(6):833-9. PMID: 15899773
  • Xu M, Bruno E, Chao J, Ni H, Lindgren V, Nunez R, Mahmud N, Finazzi G, Fruchtman SM, Popat U, Liu E, Prchal JT, Rondelli D, Barosi G, Hoffman R. The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood. 2005 Feb 15;105(4):1699-705. Epub 2004 Oct 7. PMID: 15471948
  • Xu M, Bruno E, Chao J, Huang S, Finazzi G, Fruchtman SM, Popat U, Prchal JT, Barosi G, Hoffman R; MPD Research Consortium. Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood. 2005 Jun 1;105(11):4508-15. Epub 2005 Feb 10. PMID: 1575794
  • Massa M, Rosti V, Ramajoli I, Campanelli R, Pecci A, Viarengo G, Meli V, Marchetti M, Hoffman R, Barosi G. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005 Aug 20;23(24):5688-95. PMID: 16110028 [PubMed - indexed for MEDLINE]
  • Goerttler PS, März E, Johansson PL, Andreasson B, Kutti J, Moliterno AR, Marchioli R, Spivak JL, Pahl HL. Thrombotic and bleeding complicationsin four subpopulations of patients with ET defined by c-Mpl protein expression and PRV-1 mRNA levels. Haematologica 2005;90:851-3
  • Stephen Huang, Minjiang Xu, Edward Bruno, Giovanni Barosi, Josef Prchal, and Ronald Hoffman. HMGA2, a Member of the High Mobility Group Gene Family, Is Expressed at the Protein Level in Peripheral Blood CD34+ Cells of Patients with Idiopathic Myelofibrosis and Polycythemia Vera. Blood (ASH Annual Meeting Abstracts), Nov 2004; 104: 798.
  • Jaroslav F. Prchal, Guido Finazzi, Yves D. Pastore, Murali M. Chintagumpala, Josef T. Prchal McGill. Essential Thrombocythemia in Children. Blood, Nov 16, 2003, 102, (11): 3417 (Abstract).
  • Yves D. Pastore, Jerry L. Spivak, Elizabeth M. Kurczynski, Guido Finazzi, Donna DiMichele, Hulya Ozsahin, Ronald Hoffman, Heike L. Pahl, Richard T. Silver, Josef T. Prchal, Jaroslav F. Prchal. Report on 12 Children with Polycythemia Vera. Blood, Nov 16, 2003, 102 (11): 1877 (Abstract).
  • Philipp Goerttler, Edith Doerner, Peter L. Johansson, Bjoern Andreasson, Jack Kutti, Alice R. Moliterno, Roberto Marchioli, Jerry L. Spivak, Heike L. Pahl. Thrombotic Complications in Four Subpopulations of Patients with ET Defined by c-Mpl Protein Expression and PRV-1 mRNA Levels. Blood, Nov 16, 2003,102 (11): 3415
  • Yves D. Pastore, Jerry L. Spivak, Elizabeth M. Kurczynski, Guido Finazzi, Donna DiMichele, Hulya Ozsahin, Ronald Hoffman, Heike L. Pahl, Richard T. Silver, Josef T. Prchal, Jaroslav F. Prchal. Report on 12 Children with Polycythemia Vera. Blood Nov 16, 2003, 102, (11): 1877 (Abstract).
  • Damiano Rondelli, Gianni Barosi, Andrea Bacigalupo, Joseph T. Prchal, Uday Popat, Emilio P. Alessandrino, Jerry L. Spivak, Ronald Hoffman, Steven Fruchtman. Blood, Nov 16, 2003 102, (11): 695 (Abstract).
  • Philipp Goerttler, Edith Doerner, Peter L. Johansson, Bjoern Andreasson, Jack Kutti, Alice R. Moliterno, Roberto Marchioli, Jerry L. Spivak, Heike L. Pahl. [3415] Thrombotic Complications in Four Subpopulations of Patients with ET Defined by c-Mpl Protein Expression and PRV-1 mRNA Levels. Session Type: Poster Session 635-III